Chengdu Ruimu Biopharmaceutical Technology

Chengdu Ruimu Biopharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, focused on developing innovative ophthalmic therapies. Founded in 2018 by overseas returnee scientists, the company utilizes a proprietary drug delivery platform to create eye drops capable of reaching the fundus, offering a non-invasive alternative to traditional intravitreal injections. Its lead product candidate, RM301B, is a dexamethasone-based formulation currently in Phase 1 clinical trials for the treatment of macular edema associated with retinal vein occlusion. The company has secured strategic investments from Renhe Pharmacy and Sichuan Venture Capital, positioning itself as a leader in the development of convenient and effective treatments for serious eye conditions like AMD and uveitis.